| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $116,635,307 | 44 | 100 |
| Ball Titus B. | Principal Accounting Officer | 0 | $0 | 2 | $74,485 | $-74,485 |
| Rosenberg Aaron | Chief Financial Officer | 0 | $0 | 1 | $345,659 | $-345,659 |
| Sanders Corazon (Corsee) D. | director | 0 | $0 | 2 | $1.79M | $-1.79M |
| Wang Lai | Global Head of R&D | 0 | $0 | 7 | $4.1M | $-4.1M |
| Wang Xiaodong | Chair, Scientific Advisory Brd | 0 | $0 | 2 | $11.51M | $-11.51M |
| Lee Chan Henry | SVP, General Counsel | 0 | $0 | 13 | $12.44M | $-12.44M |
| Wu Xiaobin | President and COO | 0 | $0 | 9 | $36.12M | $-36.12M |
| OYLER JOHN | Chief Executive Officer | 0 | $0 | 8 | $50.24M | $-50.24M |
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
Over the last 12 months, insiders at BeOne Medicines Ltd. have bought $0 and sold $116.64M worth of BeOne Medicines Ltd. stock.
On average, over the past 5 years, insiders at BeOne Medicines Ltd. have bought $0 and sold $153.59M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-04-08 | Sale | Lee Chan Henry | SVP, General Counsel | 332 0.0003% | $311.59 | $103,448 | +0.41% | |
| 2026-03-11 | Sale | Lee Chan Henry | SVP, General Counsel | 341 0.0003% | $300.00 | $102,300 | -2.81% | |
| 2026-02-04 | Sale | Lee Chan Henry | SVP, General Counsel | 1,660 0.0015% | $349.52 | $580,197 | -11.52% | |
| 2026-01-07 | Sale | Lee Chan Henry | SVP, General Counsel | 664 0.0006% | $331.76 | $220,289 | -3.95% | |
| 2025-12-16 | Sale | OYLER JOHN | Chief Executive Officer | 24,369 0.0207% | $302.87 | $7.38M | +3.33% | |
| 2025-12-15 | Sale | OYLER JOHN | Chief Executive Officer | 75,631 0.0651% | $307.79 | $23.28M | +1.20% | |
| 2025-12-11 | Sale | Lee Chan Henry | SVP, General Counsel | 332 0.0003% | $325.00 | $107,900 | -2.01% | |
| 2025-12-10 | Sale | Lee Chan Henry | SVP, General Counsel | 332 0.0003% | $318.28 | $105,669 | -2.55% | |
| 2025-11-26 | Sale | Sanders Corazon (Corsee) D. | director | 2,627 0.0025% | $340.90 | $895,534 | -6.15% | |
| 2025-11-17 | Sale | Wu Xiaobin | President and COO | 3,991 0.0042% | $380.43 | $1.52M | -14.85% | |
| 2025-11-13 | Sale | Wu Xiaobin | President and COO | 6,009 0.0064% | $380.54 | $2.29M | -12.90% | |
| 2025-11-12 | Sale | Wu Xiaobin | President and COO | 10,000 0.01% | $356.02 | $3.56M | -14.80% | |
| 2025-11-12 | Sale | Lee Chan Henry | SVP, General Counsel | 996 0.001% | $349.17 | $347,770 | -14.80% | |
| 2025-10-08 | Sale | Lee Chan Henry | SVP, General Counsel | 10,671 0.0105% | $350.40 | $3.74M | -8.77% | |
| 2025-09-16 | Sale | OYLER JOHN | Chief Executive Officer | 27,803 0.0253% | $325.71 | $9.06M | -1.38% | |
| 2025-09-10 | Sale | Lee Chan Henry | SVP, General Counsel | 10,006 0.0091% | $325.53 | $3.26M | +3.32% | |
| 2025-09-09 | Sale | Wang Lai | Global Head of R&D | 5,000 0.0049% | $350.06 | $1.75M | -7.83% | |
| 2025-09-05 | Sale | Sanders Corazon (Corsee) D. | director | 2,665 0.0025% | $337.00 | $898,105 | -4.86% | |
| 2025-09-02 | Sale | Ball Titus B. | Principal Accounting Officer | 122 0.0001% | $326.76 | $39,865 | -1.80% | |
| 2025-08-14 | Sale | Wu Xiaobin | President and COO | 39,936 0.0341% | $305.06 | $12.18M | +3.78% |
| Increased Positions | 174 | +67.18% | 2M | +6.66% |
| Decreased Positions | 109 | -42.08% | 1M | -3.91% |
| New Positions | 60 | New | 351,665 | New |
| Sold Out Positions | 38 | Sold Out | 143,997 | Sold Out |
| Total Postitions | 324 | +25.1% | 34M | +2.75% |